Dr. Jason Thomas Shumadine, MD

Dr. Shumadine practices at Sinai Hospital of Baltimore in Baltimore, Maryland, part of LifeBridge Health.

Dr. Shumadine's NPI, 1609079151, was assigned on June 11, 2007. Dr. Shumadine graduated from Eastern Virginia Medical School in 2004. Dr. Shumadine holds Virginia license 0101238679.

Dr. Shumadine's primary practice is Sinai Hospital of Baltimore, at 2401 West Belvedere Avenue, Baltimore, MD 21215 in Baltimore City. The practice phone is (410) 601-9000.

Dr. Shumadine's primary practice is Sinai Hospital of Baltimore in Baltimore, Maryland, part of LifeBridge Health. Dr. Shumadine is also affiliated with Carroll Hospital. The medical group on file is Sinai Rehab Pain Medicine Associates. Dmand AI also links Dr. Shumadine to 1 more medical group, named with a free account. Dr. Shumadine's employer is on file too: a hospital.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Shumadine practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Shumadine's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dmand AI has Dr. Shumadine's licenses on file in 3 states: Virginia, Florida and Louisiana.

CMS data shows 3,198 Medicare services from Dr. Shumadine across 18 procedure codes in 2024, for 238 Medicare patients. Medicare paid $253,264 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 238 Medicare patients who saw Dr. Shumadine in 2024. The largest group is 65 to 74, with 114 patients. 75% of them have cancer, and 75% have high blood pressure. 21% are also on Medicaid. Their average risk score is 1.82, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Shumadine's median patient age at 73, with 62% women.

In 2024, Dr. Shumadine wrote 246 Medicare Part D claims for 100 patients. 82% of them were for generic drugs. CMS names the drug for 158 of them, across 8 drugs with 11 or more claims each, at $2,256 in total drug cost. In 2023, CMS named 96 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Shumadine for performance year 2024, reported individually.

CMS Open Payments shows 107 general payments to Dr. Shumadine from 22 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 72% of the total. Palette Life Sciences, Inc. paid the most, $1,216.

Dr. Shumadine graduated from Eastern Virginia Medical School in 2004.